File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: Is it cost-effective?

TitleMonitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: Is it cost-effective?
Authors
Issue Date2002
PublisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/ygyno
Citation
Gynecologic Oncology, 2002, v. 84 n. 1, p. 7-11 How to Cite?
AbstractObjective. The aim of this study was to assess the cost-effectiveness of serial squamous cell carcinoma antigen (SCC) monitoring in the clinical setting. Methods. All patients with squamous cell carcinoma of the cervix and SCC measurement from 1994 to 1999 were reviewed. The cost of the investigations, including blood tests, X rays, and computer tomography; and clinic visits were adjusted to 2001 dollars for all cases over the 6-year study period. The effectiveness measure was the number of cases detected by SCC monitoring before the onset of clinical symptoms or abnormal physical examination findings. Altered clinical management due to early detection was considered successful. Results. Two thousand eight hundred fifty-one SCC antigen assays were performed from 384 patients. An elevated pretreatment SCC level was associated with poorer cumulative survival over time (P < 0.05). Fifty-five patients had recurrences, with 10 local and 45 distant recurrences. SCC levels were elevated in 47 patients (85%). The median lead time was 7.8 months. The cost of finding 1 recurrence was US$4750. SCC monitoring does not after clinical management and has no advantage over clinical examination in detecting local recurrence. Most of the recurrent diseases were detected too late for curative treatment. Only 1 patient, in whom the diagnosis could have been made by clinical examination without SCC monitoring, may have potentially benefited from exenteration. Conclusion. Posttreatment SCC monitoring is not cost-effective in the absence of curative treatment for distant spread of disease. © 2002 Elsevier Science.
Persistent Identifierhttp://hdl.handle.net/10722/87098
ISSN
2015 Impact Factor: 4.198
2015 SCImago Journal Rankings: 2.284
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, YMen_HK
dc.contributor.authorNg, TYen_HK
dc.contributor.authorNgan, HYSen_HK
dc.contributor.authorWong, LCen_HK
dc.date.accessioned2010-09-06T09:25:18Z-
dc.date.available2010-09-06T09:25:18Z-
dc.date.issued2002en_HK
dc.identifier.citationGynecologic Oncology, 2002, v. 84 n. 1, p. 7-11en_HK
dc.identifier.issn0090-8258en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87098-
dc.description.abstractObjective. The aim of this study was to assess the cost-effectiveness of serial squamous cell carcinoma antigen (SCC) monitoring in the clinical setting. Methods. All patients with squamous cell carcinoma of the cervix and SCC measurement from 1994 to 1999 were reviewed. The cost of the investigations, including blood tests, X rays, and computer tomography; and clinic visits were adjusted to 2001 dollars for all cases over the 6-year study period. The effectiveness measure was the number of cases detected by SCC monitoring before the onset of clinical symptoms or abnormal physical examination findings. Altered clinical management due to early detection was considered successful. Results. Two thousand eight hundred fifty-one SCC antigen assays were performed from 384 patients. An elevated pretreatment SCC level was associated with poorer cumulative survival over time (P < 0.05). Fifty-five patients had recurrences, with 10 local and 45 distant recurrences. SCC levels were elevated in 47 patients (85%). The median lead time was 7.8 months. The cost of finding 1 recurrence was US$4750. SCC monitoring does not after clinical management and has no advantage over clinical examination in detecting local recurrence. Most of the recurrent diseases were detected too late for curative treatment. Only 1 patient, in whom the diagnosis could have been made by clinical examination without SCC monitoring, may have potentially benefited from exenteration. Conclusion. Posttreatment SCC monitoring is not cost-effective in the absence of curative treatment for distant spread of disease. © 2002 Elsevier Science.en_HK
dc.languageengen_HK
dc.publisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/ygynoen_HK
dc.relation.ispartofGynecologic Oncologyen_HK
dc.subject.meshAntigens, Neoplasm - blooden_HK
dc.subject.meshCarcinoma, Squamous Cell - immunologyen_HK
dc.subject.meshCost-Benefit Analysisen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshMonitoring, Immunologic - economics - methodsen_HK
dc.subject.meshNeoplasm Invasivenessen_HK
dc.subject.meshNeoplasm Recurrence, Local - immunologyen_HK
dc.subject.meshNeoplasm Stagingen_HK
dc.subject.meshPredictive Value of Testsen_HK
dc.subject.meshSerpinsen_HK
dc.subject.meshSurvival Rateen_HK
dc.subject.meshUterine Cervical Neoplasms - immunologyen_HK
dc.titleMonitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: Is it cost-effective?en_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0090-8258&volume=84&issue=1&spage=7&epage=11&date=2002&atitle=Monitoring+of+serum+squamous+cell+carcinoma+antigen+levels+in+invasive+cervical+cancer:+is+it+cost-effective?en_HK
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1006/gyno.2001.6497en_HK
dc.identifier.pmid11748969-
dc.identifier.scopuseid_2-s2.0-0036144324en_HK
dc.identifier.hkuros67406en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036144324&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume84en_HK
dc.identifier.issue1en_HK
dc.identifier.spage7en_HK
dc.identifier.epage11en_HK
dc.identifier.isiWOS:000173225600003-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridChan, YM=7403676661en_HK
dc.identifier.scopusauthoridNg, TY=7402229853en_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK
dc.identifier.scopusauthoridWong, LC=7402092003en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats